Safety of Rx Optimisation Post AHF Hospitalization

This section presents a concise, high-yield summary of the video’s core content, designed as a quick reference for Healthcare Professionals (HCPs).

Note: This content was developed by our editorial team and was not reviewed or endorsed by the video speaker.

Q1. Why is early post-AHF optimization necessary?
The first 6–12 weeks post-AHF carry the highest risk of rehospitalization and death. Patients discharged without GDMT intensification often remain undertreated for prolonged periods, missing a critical therapeutic opportunity. [1] 

Q2. Is it safe to start ARNI in-hospital or early post-discharge?
Evidence from PIONEER-HF and TRANSITION demonstrates greater NT-proBNP reduction, feasible titration, and comparable safety to ACE inhibitors, supporting early implementation. [2,3] 

Q3. How do SGLT2 inhibitors perform during the post-AHF window?
EMPULSE and SOLOIST-WHF show that SGLT2 inhibitors initiated in-hospital or early post-discharge reduce HF events and improve “clinical wins” without renal penalty, even at lower eGFR thresholds. [4,5] 

Q4. Which GDMT components face the greatest real-world barriers?
β-blockers show the lowest target-dose attainment and highest physician hesitation, despite large outcome benefits. SGLT2 inhibitors are the most feasible early component. [4,5] 

Q5. What guides safe uptitration in this setting?
Blood pressure, heart rate, potassium, eGFR, congestion, and NT-proBNP trajectories provide practical safety gates for decision-making, consistent with STRONG-HF methods.

Q6. What happens if GDMT initiation is deferred to the outpatient setting?
Data from Vietnamese centers shows minimal improvement in therapy adoption 1 year after discharge if not initiated in-hospital, making discharge the optimal intervention point. [1] 

Q7. What implementation strategies improve success?
A structured, protocolized, team-based model with biomarker monitoring, short-interval follow-up, and predefined safety gates improves feasibility and clinician confidence.[1]

Q8. What is the overarching goal of post-AHF optimization?
To rapidly transition patients from unstable AHF hospitalization to stabilized, disease-modified chronic HF with minimized residual congestion and reduced early events. [1]